Technical Analysis for TAIPY - Taisho Pharmaceutical Holdings ADR

Grade Last Price % Change Price Change
grade D 15.39 2.40% 0.3600
TAIPY closed up 2.4 percent on Thursday, October 29, 2020, on 36 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical TAIPY trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Wide Range Bar Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 2.40%
NR7 Range Contraction 2.40%
Older End-of-Day Gignals for TAIPY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, and sells over-the-counter (OTC) drugs and prescription pharmaceuticals in Japan and internationally. It operates in two segments, Self-Medication Operation Group and Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments, as well as gargles, hand-washing treatments, and face masks; the RiUP series of hair re-growth treatment products; the Taisho Kampo Ichoyaku series of gastrointestinal treatment products; the Colac series of laxative products; and Livita series of food products for specialized health use, as well as engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including ZOSYN, an injectable antibiotic; Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; OZEX and Geninax, quinolone antibacterial; Bonviva, a bisphosphonate antiresorptive agent; Biofermin, a live lactobacillus preparation; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
Health Pharmaceuticals Pharmaceutical Industry Drugs Pharmacy Diabetes Food Products Pharmaceutical Industry In China Medication Pharmaceuticals Policy Skin Care Products Energy Drinks Facility Management Metabolic Diseases Medical Prescription Real Estate Leasing Clinical Pharmacology Over The Counter Drug Prescription Drug Prescription Pharmaceuticals

Is TAIPY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 19.4
52 Week Low 12.11
Average Volume 5,629
200-Day Moving Average 15.4703
50-Day Moving Average 15.7937
20-Day Moving Average 15.9298
10-Day Moving Average 15.6883
Average True Range 0.3928
ADX 12.81
+DI 28.7653
-DI 25.5261
Chandelier Exit (Long, 3 ATRs ) 15.5016
Chandelier Exit (Short, 3 ATRs ) 16.1285
Upper Bollinger Band 16.7643
Lower Bollinger Band 15.0953
Percent B (%b) 0.18
BandWidth 10.4772
MACD Line -0.1500
MACD Signal Line -0.0309
MACD Histogram -0.1191
Fundamentals Value
Market Cap 4.91 Billion
Num Shares 319 Million
EPS 1.76
Price-to-Earnings (P/E) Ratio 8.72
Price-to-Sales 1.74
Price-to-Book 0.74
Dividend 0.28
Dividend Yield 1.82%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.7099
Resistance 3 (R3) 16.7099 16.2699 16.4899
Resistance 2 (R2) 16.2699 15.9338 16.2699 16.4165
Resistance 1 (R1) 15.8300 15.7262 15.6100 15.8300 16.3432
Pivot Point 15.3900 15.3900 15.2801 15.3900 15.3900
Support 1 (S1) 14.9501 15.0539 14.7301 14.9501 14.4368
Support 2 (S2) 14.5101 14.8463 14.5101 14.3635
Support 3 (S3) 14.0702 14.5101 14.2901
Support 4 (S4) 14.0702